Haaf J A, Maigret C, Andringa-Bakker E A, van Wimersma Greidanus T B
Acta Endocrinol (Copenh). 1987 Jan;114(1):96-101. doi: 10.1530/acta.0.1140096.
Intracerebroventricular administration of dynorphin-(1-13) inhibits dose-dependently plasma vasopressin level in normal as well as in water-deprived rats, whereas systemic (subcutaneous) administration of this opioid peptide is ineffective in this respect. Simultaneous subcutaneous, but not intracerebroventricular, administration of naloxone prevents the suppressive effect of dynorphin-(1-13) on plasma vasopressin levels.
向正常大鼠以及缺水大鼠脑室内注射强啡肽-（1-13）可剂量依赖性地抑制血浆血管加压素水平，而在这方面，该阿片肽的全身（皮下）给药无效。同时皮下注射而非脑室内注射纳洛酮可阻止强啡肽-（1-13）对血浆血管加压素水平的抑制作用。
